Human umbilical cord Wharton's jelly-derived mesenchymal stem cell transplantation could improve diabetic intracavernosal pressure

Wu, Jianhong; Wang, Dong-Ya; Lü, Sheng; Qian, Weiqing; Xia, Shujie; Jiang, Qi

doi:10.4103/aja.aja_33_21

Cited by 7 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Shin et al found that HUC-MSC transplantation improved urinary function in DM rats, which provides a rationale for HUC-MSC treatment of DM-related detrusor underactivity (DUA) (124). Wu et al found that HUC-MSC transplantation may improve diabetic erectile dysfunction in rats by increasing the production of paracrine growth factors (VEGF), endothelial nitric oxide synthase (eNOS), IGF1, and basic fibroblast growth factor (bFGF) (125). In conclusion, transplantation of HUC-MSCs may be a new potential therapeutic option for DAN.…”

Section: Diabetic Autonomic Neuropathymentioning

confidence: 99%

Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances

Li,

Guan

et al. 2023

Int. J. Med. Sci.

View full text Add to dashboard Cite

Diabetes mellitus and its complications pose a major threat to global health and affect the quality of life and life expectancy of patients. Currently, the application of traditional therapeutic drugs for diabetes mellitus has great limitations and can only temporarily control blood glucose but not fundamentally cure it. Mesenchymal stem cells, as pluripotent stromal cells, have multidirectional differentiation potential, high self-renewal, immune regulation, and low immunogenicity, which provide a new idea and possible development direction for diabetes mellitus treatment. Regenerative medicine with mesenchymal stem cells treatment as the core treatment will become another treatment option for diabetes mellitus after traditional treatment. Recently, human umbilical cord mesenchymal stem cells have been widely used in basic and clinical research on diabetes mellitus and its complications because of their abundance, low ethical controversy, low risk of infection, and high proliferation and differentiation ability. This paper reviews the therapeutic role and mechanism of human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications and highlights the challenges faced by the clinical application of human umbilical cord mesenchymal stem cells to provide a more theoretical basis for the application of human umbilical cord mesenchymal stem cells in diabetes mellitus patients.

show abstract

Section: Diabetic Autonomic Neuropathymentioning

confidence: 99%

Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances

Li,

Guan

et al. 2023

Int. J. Med. Sci.

View full text Add to dashboard Cite

show abstract

Application of mesenchymal stem cells derived from the umbilical cord or Wharton’s jelly and their extracellular vesicles in the treatment of various diseases

Patel,

Mohamed,

Rizaev

et al. 2024

Tissue and Cell

View full text Add to dashboard Cite

Biodegradable nano black phosphorus based SDF1-α delivery system ameliorates Erectile Dysfunction in a cavernous nerve injury rat model by recruiting endogenous stem/progenitor cells

Fu,

Song,

et al. 2023

J Nanobiotechnol

View full text Add to dashboard Cite

Stem cell (SC) therapy has been shown high prospects in erectile dysfunction (ED) treatment. Without ethical issues and risks of immune rejection and tumorigenesis of exogenous SC therapy, endogenous stem/progenitor cells (S/PCs) have a better potential for ED management, and their homing and redistribution are controlled by SDF1-α/CXCR4 axis. Considering black phosphorus nanosheet (BPNS) has emerged as an efficient and safe drug vehicle due to its large surface area, biodegradability, and the ability to retain and slowly release its loaded drugs, BPNS is utilized to load SDF1-α, a chemokine for S/PCs, to construct the BP@SDF1-α complex to efficiently recruit stem cells (SCs) by injury-site injection and thus ameliorate ED within the bilateral cavernous nerve injury (BCNI) rat models. We find that BP@SDF1-α can efficiently recruit exogenous SCs and endogenous S/PCs to corpus cavernosum and main pelvic ganglion (MPG) by local administration. Of note, ascribing to endogenous S/PCs recruitment, it also successfully alleviates ED in BCNI rat models by enhancing the protein expression levels of α-SMA, CD31, and nNOs, and eliciting less collagen deposition in the penis after its combined injection at corpus cavernosum and MPG. Thus, this study provides a new insight into the treatment of ED with endogenous S/PCs. Biodegradable Nano Black Phosphorus based SDF1-α delivery system ameliorates Erectile Dysfunction in a cavernous nerve Injury Rat Model by recruiting endogenous Stem/Progenitor cells

show abstract

Human umbilical cord Wharton's jelly-derived mesenchymal stem cell transplantation could improve diabetic intracavernosal pressure

Cited by 7 publications

References 45 publications

Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances

Human umbilical cord mesenchymal stem cells in diabetes mellitus and its complications: applications and research advances

Application of mesenchymal stem cells derived from the umbilical cord or Wharton’s jelly and their extracellular vesicles in the treatment of various diseases

Biodegradable nano black phosphorus based SDF1-α delivery system ameliorates Erectile Dysfunction in a cavernous nerve injury rat model by recruiting endogenous stem/progenitor cells

Contact Info

Product

Resources

About